Dr. Melissa Kagarise, PA C
|
|
- Philomena Heath
- 6 years ago
- Views:
Transcription
1 Dr. Melissa Kagarise, PA C This program has been supported by an educational grant from Pfizer Pharmaceuticals PharmCon is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education Legal Disclaimer: The material presented here does not necessarily reflect the views of Pharmaceutical Education Consultants (PharmCon) or the companies that support educational programming. A qualified healthcare professional should always be consulted before using any therapeutic product discussed. Participants should verify all information and data before treating patients or employing any therapies described in this educational activity.
2 Accreditation: Pharmacists L01-P Technicians L01-T Target Audience: Pharmacists & Technicians CE Credits: 1.0 Credit hour or 0.1 CEU for pharmacists/technicians Expiration Date: 05/18/2012 Program Overview: Overactive Bladder is a bothersome medical condition that affects more than 17 million men and women of all ages. This program will assist pharmacists identify, counsel and treat patients who seek control of their overactive bladders, as well as enhance their knowledge of currently available treatment options (along with their probable results and possible side effects), and offers counseling points for patients and their families in overcoming their embarrassment and seeking treatment. Objectives: Review the epidemiology and etiology of overactive bladder. Identify the pharmacological bladder control options for patients suffering from urinary incontinence, to include their mechanisms of action, efficacy, dosing, safety, and tolerability profiles. Review other available treatment options (such as behavioral and life style) that can mitigate overactive bladder. Describe the proactive role that pharmacists can play in identifying, counseling, and treating patients seeking relief from overactive bladder. This program has been supported by an educational grant from Pfizer Pharmaceuticals
3 Speaker: Dr. Melissa Kagarise is a primary care physician assistant who practices at a free medical clinic in Altoona, PA. She is an assistant professor at Saint Francis University and Program Director for the SFU/CERMUSA Physician Assistant program. She obtained her physician assistant degree through SFU and completed her doctoral studies in health sciences through Nova Southeastern University. Speaker Disclosure: Dr. Kagarise has no actual or potential conflicts of interest in relation to this program This program has been supported by an educational grant from Pfizer Pharmaceuticals PharmCon is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education Legal Disclaimer: The material presented here does not necessarily reflect the views of Pharmaceutical Education Consultants (PharmCon) or the companies that support educational programming. A qualified healthcare professional should always be consulted before using any therapeutic product discussed. Participants should verify all information and data before treating patients or employing any therapies described in this educational activity.
4 Educational Objectives 1. Review the epidemiology and etiology of overactive bladder. 2. Review non pharmacological treatment options. 3. Identify the pharmacological bladder control options, including mechanism of action, efficacy, dosing, safety and tolerability profiles. 4. Describe the proactive role of pharmacists in identifying, counseling and treating patients.
5 Overactive Bladder Urinary urgency Urge incontinence Urinary frequency Nocturia
6 Prevalence Estimated 34 million men and women Prevalence 2002, 9 16% Women>Men 15 50% of women 1.5 5% of men Costs $19.5 billion/year managing incontinence $12.6 billion/year managing overactive bladder
7 Physiology
8 Process of Urination Combination of automatic and conscious muscle actions Emptying phase Filling/storage phase Automatic cholinergic and adrenergic neurotransmitters serotonin and noradrenaline Conscious voluntarily contraction of external sphincter muscles
9 Pathophysiology Neurogenic Myogenic
10 Clinical Assessment History Symptoms Medications Diuretics Antidepressants Alpha agonists Alpha antagonists Beta antagonists Sedatives Anticholinergics Analgesics
11 Clinical Assessment Physical Examination Testing Urinary Track Infections Benign Prostatic Hypertrophy, Diabetes, Mellitus Neurological conditions (Multiple Sclerosis, Stroke, Alzheimer's disease, Spinal Cord Injury or Stenosis)
12 Effects of OAB Emotional Depression Loneliness, shame, helplessness, introversion, lack of confidence Disruption of Daily living Advance planning Loss of independence Stop exercising
13 Goals in Treatment Diminish Symptoms Prevent Complications Improve Quality of Life
14 Treatment Approach Behavioral Pharmacological Surgical
15 Abrams et al 2005
16 Behavioral Modifications
17 Dietary Considerations Weight control Fluid Control Food restrictions Caffeinated beverages Alcoholic beverages Citrus fruits and juices, tomatoes/products Chocolate Sugars, artificial sweeteners
18
19 Pelvic Floor Muscle Training Kegel Exercises Contraction and relaxation of pelvic floor muscles
20 Pharmacologic Treatment Antimuscarinics/Anticholinergic Alpha Adrenergic Agonists Estrogen Tricyclic antidepressants/ Serotonin Norepinephrine Reuptake Inhibitors Capsaicin and analogs Botulinum toxin type A
21 Antimuscarinic/Anticholinergic Block the cholinergic muscarinic receptors (M2 and M3) M2, smooth muscle, hindbrain, cardiac M3, smooth muscle, salivary gland, eye Inhibit involuntary contractions of the bladder Increase bladder capacity Delay initial urge to void
22 Anticholinergic Side Effects Side Effects a result of peripheral and central anticholinergic action Dry as a Bone Blind as a Bat Red as a Beet Hot as Hades Mad as a Hatter
23 Generic name Brand Name Initial Dose Maximum Dose Side Effect/Dry Mouth Darifenacin Enablex Oxybutynin* Ditropan Oxybutynin LA* Ditropan LA Oxybutynin patch Oxytrol Solifenacin Vesicare Tolterodine* Detrol Tolterodine LA* Detrol LA Trospium Sanctura 7.5 mg qd 15 mg qd in 20.2% and 35.3% 5 mg bid or tid 5 mg qid Common 5 mg qd 30 Mg qd 60.8% 3.9 mg/day patch twice weekly 3.9 mg/day patch twice weekly 12% 5 mg qd 10 mg qd 10% and 27.6% 1 2 mg bid 2 mg bid 35% 2 4 mg qd 4 mg qd 23% 20 mg bid 20 mg bid 20.1%
24 Solifenacin (Vesicare) Mechanism of Action Inhibits primarily M3 muscarinic receptors Dosage 5 mg once daily to 10mg once daily; taken with liquid and swallowed whole, with or without food Altered pharmacokinetics with Ketoconazole maximum dose 5 mg
25 Vesicare Contraindications Urinary Retention Gastric Retention Un controlled narrow angle glaucoma Allergy Precautions Impaired Renal or reduced hepatic function Do not exceed 5 mg/day dosing
26 Darifenacin (Enablex) Mechanism of Action Selective muscarinic M3 reactor antagonist Dosage 7.5 mg once daily, can be increased to 15 mg once daily after 2 weeks Extended release tablets to be taken whole with liquid
27 Enablex Side Effects Dry mouth Constipation Dyspepsia, abdominal pain, nausea, diarrhea, dizziness Drug interactions Ketoconazole and Itraconazole Do not exceed 7.5mg of Enablex Contraindications Urinary retention, gastric retention, uncontrolled narrow angle glaucoma
28 Alpha adrenergic agonists Mimic norepinephrine to stimulate alpha adrenergic receptors Contraction of urethral smooth muscle to tighten the urinary sphincter and valve Ephedrine and Pseudoephedrine Side effects Agitation, insomnia, anxiety, dry mouth, headache Precaution Use Glaucoma, diabetes, hyperthyroidism, hypertension
29 Estrogen Helps maintain the strength and flexibility of bladder and urethral tissues Improve blood flow, enhance nerve function and correct tissue deterioration Prescribed as cream Increase risk of heart disease, stroke and breast cancer
30 Tricyclic Antidepressants Imipramine (Tofranil) Anticholinergic effects Alpha adrenergic effects Bladder relaxation while causing bladder neck smooth muscles to contract Side Effects Drowsiness, irregular heartbeat, dizziness, orthostatic hypotension, dry mouth, blurred vision, constipation
31 Capsaicin Extract from hot chili peppers Thought to numb the hypersensitive bladder Administered through catheter Stimulates sensory nerves of bladder Produces long term resistance to sensory activation Side Effects Temporary discomfort and burning
32 Botulinum toxin type A Blocks the actions of acetylcholine and relaxes the bladder muscle Investigational
33
Overactive bladder (OAB) affects approximately 15% of the adult population. Diagnosis is based
Overactive bladder (OAB) affects approximately 15% of the adult population. Diagnosis is based upon a medical history, and includes a focused physical exam (abdominal, neurological, pelvic in females and
More informationURGE MOTOR INCONTINENCE
URGE MOTOR INCONTINENCE URGE INCONTINENCE COMMONEST TYPE IN ELDERLY WOMEN Causes: 1 - Defects in CNS regulation Stroke Parkinson s disease Dementia (Alzheimer s and other types) Normopressure hydrocephalus
More informationTHE OVER-ACTIVE BLADDER (OAB)
THE OVER-ACTIVE BLADDER (OAB) Passage of urine is caused by the bladder muscle contracting coordinated with the relaxation of the sphincter muscles, which is controlled by higher centers in the central
More informationObjectives. Prevalence of Urinary Incontinence URINARY INCONTINENCE: EVALUATION AND CURRENT TREATMENT OPTIONS
URINARY INCONTINENCE: EVALUATION AND CURRENT TREATMENT OPTIONS Lisa S Pair, MSN, CRNP Division of Urogynecology and Pelvic Reconstructive Surgery Department of Obstetrics and Gynecology University of Alabama
More informationUrinary Incontinence for the Primary Care Provider
Urinary Incontinence for the Primary Care Provider Diana J Scott FNP-BC https://youtu.be/gmzaue1ojn4 1 Assessment of Urinary Incontinence Urge Stress Mixed Other overflow, postural, continuous, insensible,
More informationOveractive Bladder Syndrome
Overactive Bladder Syndrome behavioural modifications to pharmacological and surgical treatments Dr Jos Jayarajan Urologist Austin Health, Eastern Health Warringal Private, Northpark Private, Epworth Overactive
More informationOveractive bladder can result from one or more of the following causes:
Overactive bladder can affect people of any age; however, it is more common in older people. Effective treatments are available and seeing your doctor for symptoms of overactive bladder often results in
More informationPresentation Goals 4/14/2015. Pharmacology for Urinary Incontinence in Women. Medications Review anti muscarinic medications Focus on newer meds
Presentation Goals Pharmacology for Urinary Incontinence in Women Medications Review anti muscarinic medications Focus on newer meds Introduce beta adrenergic medications Current Concepts in Drug Therapy
More informationURINARY INCONTINENCE
Center for Continence Care and Pelvic Medicine What is urinary incontinence? URINARY INCONTINENCE Urinary incontinence is the uncontrollable loss of urine. The amount of urine leaked can vary from only
More informationOveractive Bladder. When to see a doctor. Normal bladder function
Overactive Bladder Overactive bladder is a problem with bladder-storage function that causes a sudden urge to urinate. The urge may be difficult to stop, and overactive bladder may lead to the involuntary
More informationPrimary Care management of Overactive Bladder (OAB)
DERBYSHIRE JOINT AREA PRESCRIBING COMMITTEE (JAPC) Primary Care management of Overactive Bladder (OAB) Prescribing Tips All medicines for OAB have similar dose-related efficacy. More than one agent (up
More informationEvaluation and Treatment of Incontinence
Evaluation and Treatment of Incontinence Classification of Incontinence Failure to empty: Overflow incontinence Failure to store Stress Incontinence Urge Incontinence Physiology of voiding CNS Brain sends
More informationOveractive Bladder (OAB) Step Therapy Program Policy Number: Last Review: Origination: Next Review: Policy When Policy Topic is covered:
Overactive Bladder (OAB) Step Therapy Program Policy Number: 5.01.556 Origination: 07/2013 Last Review: 11/2014 Next Review: 11/2015 Policy BCBSKC will provide coverage for brand name Overactive Bladder
More informationOveractive Bladder (OAB) Step Therapy Program
Overactive Bladder (OAB) Step Therapy Program Policy Number: 5.01.556 Last Review: 11/2018 Origination: 7/2013 Next Review: 11/2019 Policy Blue Cross and Blue Shield of Kansas City (Blue KC) will provide
More informationAppendix 2 Drug Information
Appendix 2 Drug Information Chemical Name: baclofen (bak-loe-fen) Brand Name: Lioresal (U.S. and Canada) Description: Baclofen acts on the central nervous system to relieve spasms, cramping, and tightness
More informationEvaluation & Management of Overactive Bladder
Evaluation & Management of Overactive Bladder Disclosures/Conflict of Interest/Bias I have no financial relationship with any of the companies that produce the products I m about to discuss I have no conflicts
More informationContinence PGD transdermal oxybutynin Kentera patch 36mg
Continence PGD transdermal oxybutynin Kentera patch 36mg Patient group direction for the supply of transdermal oxybutynin Kentera patch 36mg to patients suffering from urinary frequency, urgency or incontinence
More informationVarious Types. Ralph Boling, DO, FACOG
Various Types Ralph Boling, DO, FACOG The goal of this lecture is to increase assessment and treatment abilities for physicians managing urinary incontinence (UI) patients. 1. Effectively communicate with
More informationOveractive Bladder. Jennifer Mosher, WHNP-BC, CUNP Mercy Health Pelvic Medicine and Urogynecology Muskegon, Michigan
Overactive Bladder Jennifer Mosher, WHNP-BC, CUNP Mercy Health Pelvic Medicine and Urogynecology Muskegon, Michigan Speaker Disclosure I have nothing to disclose. 2 Learning Objectives Define OAB Identify
More informationManagement of OAB. Lynsey McHugh. Consultant Urological Surgeon. Lancashire Teaching Hospitals
Management of OAB Lynsey McHugh Consultant Urological Surgeon Lancashire Teaching Hospitals Summary Physiology Epidemiology Definitions NICE guidelines Evaluation Conservative management Medical management
More informationDiagnosis and treatment of overactive bladder (non-neurogenic) in adults: AUA/SUFU guideline.
Diagnosis and treatment of overactive bladder (non-neurogenic) in adults: AUA/SUFU guideline. TARGET POPULATION Eligibility Decidable (Y or N) Inclusion Criterion non-neurogenic OAB Exclusion Criterion
More informationUrinary Incontinence. Lee A. Jennings, MD, MSHS. Assistant Professor Reynolds Department of Geriatrics University of Oklahoma Health Sciences Center
Urinary Incontinence Lee A. Jennings, MD, MSHS Assistant Professor Reynolds Department of Geriatrics University of Oklahoma Health Sciences Center Slides adapted from Alison Moore, MD, MPH University of
More informationBladder dysfunction in ALD and AMN
Bladder dysfunction in ALD and AMN Sara Simeoni, MD Department of Uro-Neurology National Hospital for Neurology and Neurosurgery Queen Square, London 10:15 Dr Sara Simeoni- Bladder issues for AMN patients
More informationDisclosures. Geriatric Incontinence and Voiding Dysfunction. Agenda. Agenda. UI: a Geriatric Syndrome. Geriatric Syndromes 9/7/2018.
Disclosures Geriatric Incontinence and Voiding Dysfunction None Shachi Tyagi MD, MS Assistant Professor Division of Geriatric Medicine University of Pittsburgh Medical Center UI: a Geriatric Syndrome Geriatric
More informationManagement, Evaluation, and Treatment of Overactive Bladder and Urinary Incontinence
Management, Evaluation, and Treatment of Overactive Bladder and Urinary Incontinence Arthur Mourtzinos, MD, MBA Co-Vice Chair, Institute of Urology Director, Continence Center Assistant Professor of Urology,
More informationAnticholinergic medication use for female overactive bladder in the ambulatory setting in the United States.
Página 1 de 6 PubMed darifenacin vs solifenacin Display Settings:, Sorted by Recently Added Results: 5 1. Int Urogynecol J. 2013 Oct 25. [Epub ahead of print] Anticholinergic medication use for female
More informationOveractive bladder syndrome (OAB)
Service: Urology Overactive bladder syndrome (OAB) Exceptional healthcare, personally delivered What is OAB? An overactive bladder or OAB is where a person regularly gets a sudden and compelling need or
More informationUtibron Neohaler. (indacaterol, glycopyrrolate) New Product Slideshow
Utibron Neohaler (indacaterol, glycopyrrolate) New Product Slideshow Introduction Brand name: Utibron Neohaler Generic name: Indacaterol, glycopyrrolate Pharmacological class: Long-acting beta2- agonist
More informationPatient Information. Basic Information on Overactive Bladder Symptoms. pubic bone. urethra. scrotum. bladder. vaginal canal
Patient Information English Basic Information on Overactive Bladder Symptoms The underlined terms are listed in the glossary. What is the bladder? pubic bone bladder seminal vesicles prostate rectum The
More informationVictoria Sharp, MD, MBA, FAAFP. Clinical Professor of Urology and Family Medicine
Victoria Sharp, MD, MBA, FAAFP Clinical Professor of Urology and Family Medicine Victoria Sharp, MD, MBA, FAAFP Market Chief Medial Officer AmeriHealth Caritas Family of Companies Office phone: (515) 330-3740
More informationAdvanced Care for Female Overactive Bladder & Urinary Incontinence. Department of Urology Kaiser Permanente Santa Rosa
Advanced Care for Female Overactive Bladder & Urinary Incontinence Department of Urology Kaiser Permanente Santa Rosa Goals Participants will: Review normal urinary tract anatomy and function Understand
More informationVoiding Dysfunction Block lecture, 5 th year student. Choosak Pripatnanont, Department of Surgery, PSU.
Voiding Dysfunction 2009 Block lecture, 5 th year student. Choosak Pripatnanont, Department of Surgery, PSU. Objectives Understand and explain physiologic function and dysfunction of lower urinary tract.
More informationLower Urinary Tract Symptoms (LUTS) and Nurse-Led Clinics. Sean Diver Urology Advanced Nurse Practitioner candidate Letterkenny University Hospital
Lower Urinary Tract Symptoms (LUTS) and Nurse-Led Clinics Sean Diver Urology Advanced Nurse Practitioner candidate Letterkenny University Hospital 01/02/2018 Lower Urinary Tract Symptoms LUTS - one of
More informationSome people experience occasional, minor leaks of urine. Others wet their clothes frequently.
Urinary Incontinence Urinary incontinence the loss of bladder control is a common and often embarrassing problem. The severity ranges from occasionally leaking urine when you cough or sneeze to having
More informationManagement of Female Stress Incontinence
Management of Female Stress Incontinence Dr. Arvind Goyal Associate Professor (Urology& Renal Transplant) Dayanand Medical College & Hospital, Ludhiana, Punjab, India Stress Incontinence Involuntary loss
More informationIs There a Best Drug for Overactive Bladder in a Patient with Dementia?
Is There a Best Drug for Overactive Bladder in a Patient with Dementia? Todd Semla, MS, Pharm.D., BCPS, FCCP, AGSF National PBM Clinical Pharmacy Program Manager Mental Health & Geriatrics U.S. Department
More informationURINARY INCONTINENCE. Urology Division, Surgery Department Medical Faculty, University of Sumatera Utara
URINARY INCONTINENCE Urology Division, Surgery Department Medical Faculty, University of Sumatera Utara Definition The involuntary loss of urine May denote a symptom, a sign or a condition Symptom the
More informationOveractive bladder. Information for patients from Urogynaecology
Overactive bladder Information for patients from Urogynaecology An overactive bladder (OAB) is a very common problem. It can cause distressing symptoms that are difficult to control. These can include
More informationSPASMEX FORTE 5mg tablets
PACKAGE LEAFLET: INFORMATION FOR THE USER SPASMEX FORTE 5mg tablets TROSPIUM This leaflet is a copy of the Summary of Product Characteristics and Patient Information Leaflet for a medicine, which outlines
More informationIncontinence: Risks, Causes and Care
Welcome To Incontinence: Risks, Causes and Care Presented by Kamal Masaki, MD Professor and Chair Department of Geriatric Medicine John A. Burns School of Medicine, UH Manoa September 5, 2018 10:00 11:00
More informationCauses of Transient Incontinence. Geriatrics: Urinary Incontinence, Dementia, and Delirium. Classification of Established Incontinence
Causes of Transient Geriatrics: Urinary, Dementia, and Delirium Carla Zeilmann, PharmD, BCPS St. Louis College of Pharmacy Therapeutics 3 Fall 2003 D delirium I infection A atrophic urethritis and vaginitis
More informationGeriatric Urinary Incontinence
Geriatric Urinary Incontinence Neil M. Resnick, MD Thomas Detre Professor of Medicine Chief, Division of Geriatric Medicine University of Pittsburgh/UPMC UI: The Problem Prevalence in elderly 33% Morbidity
More informationThe Management of Overactive Bladder Syndrome with Antimuscarinic Drugs
The Management of Overactive Bladder Syndrome with Antimuscarinic Drugs Author Version Date Consultation Date of Ratification By JPG Shaista Hussain Joint Formulary Pharmacist V2 16.09.2014 Homerton University
More informationLower Urinary Tract Symptoms K Kuruvilla Zachariah Associate Specialist
Lower Urinary Tract Symptoms K Kuruvilla Zachariah Associate Specialist Lower Urinary Tract Symptoms Storage Symptoms Frequency, urgency, incontinence, Nocturia Voiding Symptoms Hesitancy, poor flow, intermittency,
More informationPharmacologic management of overactive bladder
REVIEW Pharmacologic management of overactive bladder Sum Lam 1,2 lga Hilas 1,3 1 St. John s University, College of Pharmacy and Allied Health Professions, Department of Clinical Pharmacy Practice, Queens,
More informationUrinary Incontinence in Women: Never an Acceptable Consequence of Aging
Urinary Incontinence in Women: Never an Acceptable Consequence of Aging Catherine A. Matthews, MD Associate Professor Chief, Urogynecology and Pelvic Reconstructive Surgery University of North Carolina,
More informationINCONTINENCE What can Wee do about it?
Prevalence INCONTINENCE What can Wee do about it? High risk groups Myths Aetiology Assessment-History Assessment-Drugs Assessment- Examination & Tests INCONTINENCE What can wee do about it? Treatment-First
More informationDr Jonathan Evans Paediatric Nephrologist
How do I manage a patient with intractable daytime wetting: Dr Jonathan Evans Paediatric Nephrologist Of 107 children aged 11-12 with day-wetting 91 (85%) were dry at 15-16 yr Swithinbank et al BJU 1998
More informationVESIGARD Tablets (Darifenacin hydrobromide)
Published on: 10 Jul 2014 VESIGARD Tablets (Darifenacin hydrobromide) Composition VESIGARD 7.5 Extended Release Tablets Each tablet contains: Darifenacin (as a hydrobromide).. 7.5 mg Dosage Form Tablets
More informationUrinary Incontinence. Alison A Moore, MD, FACP
Urinary Incontinence Alison A Moore, MD, FACP Professor of Medicine/Geriatric Medicine David Geffen School of Medicine at UCLA Department of Medicine, Division of Geriatrics Urinary Incontinence (UI) Involuntary
More informationAn awfully overactive bladder By Katie Hayes
An awfully overactive bladder By Katie Hayes Learning objectives After reading this article you should be able to: Identify signs and symptoms of overactive bladder syndrome Describe the pharmacological
More informationUrinary Continence & Management Post Stroke
Urinary Continence & Management Post Stroke Incontinence and Stroke occurs in greater than 50% of acute stroke patients despite the personal, economic and psychosocial impact treatment evidence specific
More informationTREATMENT OF OVERACTIVE BLADDER IN ADULTS FUGA 2016 KGH
TREATMENT OF OVERACTIVE BLADDER IN ADULTS FUGA 2016 KGH CONTENTS Overactive bladder (OAB) Treatment of OAB Beta-3 adrenoceptor agonist (Betmiga ) - Panacea? LASER treatment - a flash in the pan or the
More informationRECENT ADVANCES IN THE MANAGEMENT OF URINARY INCONTINENCE
RECENT ADVANCES IN THE MANAGEMENT OF URINARY INCONTINENCE SAAD JUMA, MD INCONTINENCE RESEARCH INSTITUTE ENCINITAS, CA AUA STRESS URINARY INCONTINENCE GUIDELINE UPDATE INDEX PATIENTS The otherwise healthy
More informationNEUROGENIC BLADDER. Dr Harriet Grubb Dr Alison Seymour Dr Alexander Joseph
NEUROGENIC BLADDER Dr Harriet Grubb Dr Alison Seymour Dr Alexander Joseph OUTLINE Definition Anatomy and physiology of bladder function Types of neurogenic bladder Assessment and management Complications
More informationURGENCY INCONTINENCE FLAME LECTURE: 175 BURNS / TABIT
URGENCY INCONTINENCE FLAME LECTURE: 175 BURNS / TABIT 3.17.17 Learning Objectives Discss etiology and risk factors for rge rinary incontinence Describe the workp for rge rinary incontinence Describe management
More informationFemale Urinary Incontinence: What It Is and What You Can Do About It
Female Urinary Incontinence: What It Is and What You Can Do About It Urogynecology Patient Information Sheet What is Urinary Incontinence? Stress Incontinence is a leakage of urine that occurs, for example,
More informationIntroductory Clinical Pharmacology Chapter 32 Antiparkinsonism Drugs
Introductory Clinical Pharmacology Chapter 32 Antiparkinsonism Drugs Dopaminergic Drugs: Actions Symptoms of parkinsonism are caused by depletion of dopamine in CNS Amantadine: makes more of dopamine available
More informationY0028_2726_0 File&Use Bladder Control Does Matter
Y0028_2726_0 File&Use 04092012 Bladder Control Does Matter If you suffer from urinary incontinence, you re not alone Don t be afraid to raise your hand if you ve been struggling with the embarrassment
More informationIncontinence. Anatomy The human body has two kidneys. The kidneys continuously filter the blood and make urine.
Incontinence Introduction Urinary incontinence occurs when a person cannot control the emptying of his or her urinary bladder. It can happen to anyone, but is very common in older people. Urinary incontinence
More informationNEW ZEALAND DATA SHEET ACUPAN TM. 3. PHARMACEUTICAL FORM White, round, biconvex, film-coated tablets (7 mm diameter) engraved APN on one face.
1. PRODUCT NAME ACUPAN 30 mg tablets 2. QUALITATIVE AND QUANTITATIVE COMPOSITION Each tablet contains nefopam hydrochloride 30 mg. For a full list of excipients, see section 6.1. 3. PHARMACEUTICAL FORM
More informationInnovations in Childhood Incontinence: Neurogenic and Functional Bladder Disorders
TNe 10 Innovations in Childhood Incontinence: Neurogenic and Functional Bladder Disorders Stuart B. Bauer, MD President, ICCS Department of Urology Children s Hospital Boston Professor of Urology Harvard
More informationThese drugs produce effects similar to the sympathetic nervous system
Terms adrenergic Drugs mydriasis sympathetic nervous system adrenergic drugs adrenergic mechanism of action positive inotropic effect positive chronotropic effect positive dromotropic effect adrenergic
More informationUrinary incontinence in women & men
Urinary incontinence in women & men Dr. Blayne Welk Assistant Professor, Western University, London, ON, Canada Part 1: INCONTINENCE IN WOMEN Urinary incontinence is common. About 1 in 4 young women, and
More informationENABLEX (darifenacin)
T2004-49 ENABLEX (darifenacin) Extended-Release tablets Rx only Prescribing Information DESCRIPTION ENABLEX (darifenacin) is an extended-release tablet which contains 7.5 mg or 15 mg darifenacin as its
More informationManagement of Urinary Incontinence George A. DeMaagd, PharmD, BCPS; and Timothy C. Davenport, MD
George A. DeMaagd, PharmD, BCPS; and Timothy C. Davenport, MD DISEASE OVERVIEW Urinary incontinence (UI) may be defined as any involuntary or abnormal urine loss. UI is characterized by lower urinary tract
More informationUrogynecology in EDS. Joan L. Blomquist, MD Greater Baltimore Medical Center August 2018
Urogynecology in EDS Joan L. Blomquist, MD Greater Baltimore Medical Center August 2018 One in three like me Voiding Issues Frequency/Urgency Urinary Incontinence neurogenic bladder Neurologic supply
More informationPolicy. Medical Policy Manual Approved Revised: Do Not Implement Until 4/2/19. IncobotulinumtoxinA
IncobotulinumtoxinA NDC CODE(S) 00259-1605-XX Xeomin 50 UNIT SOLR (MERZ PHARMACEUTICAL) 00259-1610-XX Xeomin 100 UNIT SOLR (MERZ PHARMACEUTICAL) 00259-1620-XX Xeomin 200 UNIT SOLR (MERZ PHARMACEUTICAL)
More informationAccording to the INDICATIONS AND USAGE section of its FDA-approved product labeling (PI):
DEPARTMENT OF HEALTH & HUMAN SERVICES Public Health Service Food and Drug Administration Silver Spring, MD 20993 TRANSMITTED BY FACSIMILE Karen L. Walles, M.S. Assistant Director, Regulatory Affairs 3
More informationDrugs for Overactive Bladder (OAB)
ril 2014 Drugs for Overactive Bladder (OAB) FINAL CONSOLIDATED COMPREHENSIVE RESEARCH PLAN July 2015 FINAL COMPREHENSIVE RESEARCH PLAN 2 A. Introduction The objective of the drug class review on drugs
More informationTaking Control of your Bladder, or. Don't make me laugh when laughter isn't the best medicine: a discussion on urinary incontinence
Taking Control of your Bladder, or Don't make me laugh when laughter isn't the best medicine: a discussion on urinary incontinence Brett Vassallo, MD, FACOG, FAC Female Pelvic Medicine and Reconstructive
More informationWhen Laughing is No Longer Funny Managing Transient Urinary Incontinence in Hospitalized Elderly Women
When Laughing is No Longer Funny Managing Transient Urinary Incontinence in Hospitalized Elderly Women Grace Umejei, BSN, RN, CWOC. Texas Health Presbyterian Hospital Dallas NICHE Online Connect Webinars
More informationOveractive Bladder Syndrome
Page 1 of 5 Overactive Bladder Syndrome Overactive bladder syndrome is common. Symptoms include an urgent feeling to go to the toilet, going to the toilet frequently, and sometimes leaking urine before
More informationOVERACTIVE BLADDER (OAB)
OVERACTIVE BLADDER (OAB) Ms Taryn Hallam Alana Health Care for Women Women s Health Training Associates OVERACTIVE BLADDER The most misdiagnosed and misunderstood of all the urinary disorders. Problem???
More informationTricyclic Antidespressants: Actions
Introductory Clinical Pharmacology Chapter 24 Antidepressant Drugs Tricyclic Antidespressants: Actions Increase sensitivity in postsynaptic alpha (α)-adrenergic, serotonin receptors Decrease sensitivity
More informationInformation to Help You Live Life to the Fullest
Information to Help You Live Life to the Fullest For more information and to join the conversation visit: Prevail.com/LOBC 800-227-3551 CONSUMER EDUCATION 2015 First Quality Products, Inc. All rights reserved.
More informationPain CONCERN. Medicines for long-term pain. Antidepressants
Pain CONCERN Medicines for long-term pain Antidepressants Many people living with long-term pain (also known as chronic or persistent pain) are worried about using medicines like antidepressants. They
More informationUrine a Mess: Micturition Disorders Joe Bartges, DVM, PhD, DACVIM, DACVN Cornell University Veterinary Specialists Stamford, CT
Urine a Mess: Micturition Disorders Joe Bartges, DVM, PhD, DACVIM, DACVN Cornell University Veterinary Specialists Stamford, CT 1. Micturition refers to the process of storing and periodically voiding
More informationElements for a Public Summary
VI.2 Elements for a Public Summary VI.2.1 Overview of disease epidemiology Generalised anxiety disorder Generalised anxiety disorder (GAD) is an umbrella term that covers a wide range of anxiety disorders
More informationPRODUCT INFORMATION. (RS)-N,N-Dimethyl-2-[(2-methylphenyl)phenylmethoxy]ethanamine dihydrogen 2-hydroxypropane-1,2,3-tricarboxylate
NORGESIC Orphenadrine citrate and paracetamol PRODUCT INFORMATION NAME OF THE MEDICINE Active ingredient: Chemical name: CAS number: 4682-36-4 Chemical structure: Orphenadrine citrate (RS)-N,N-Dimethyl-2-[(2-methylphenyl)phenylmethoxy]ethanamine
More informationDrug Class Review Agents for Overactive Bladder
Drug Class Review Agents for Overactive Bladder Final Update 4 Report March 2009 The purpose of reports is to make available information regarding the comparative clinical effectiveness and harms of different
More informationGuidelines MANAGEMENT OF MAJOR DEPRESSIVE DISORDER (MDD)
MANAGEMENT OF MAJOR DEPRESSIVE DISORDER (MDD) Guidelines CH Lim, B Baizury, on behalf of Development Group Clinical Practice Guidelines Management of Major Depressive Disorder A. Introduction Major depressive
More informationFemale Pelvic Medicine & Reconstructive Surgery Beth Israel Deaconess Medical Center (BIDMC)
Female Pelvic Medicine & Reconstructive Surgery Beth Israel Deaconess Medical Center (BIDMC) Name: Age: Reason for visit/referral: Are you referred for or interested in surgery? Yes No Maybe Referring
More informationNorth Georgia Urology Center, P.C. Urology Patient Questionnaire
Today s Date North Georgia Urology Center, P.C. Urology Patient Questionnaire Dear Patients: to help the urologist give you better care, please take a moment of valuable time to answer the following questions.
More informationOXYSPAS Tablets (Oxybutynin chloride)
Published on: 10 Jul 2014 OXYSPAS Tablets (Oxybutynin chloride) Composition OXYSPAS-2.5 Tablets Each uncoated tablet contains Oxybutynin chloride... 2.5 mg OXYSPAS-5 Tablets Each uncoated tablet contains
More informationFEMALE URINARY INCONTINENCE: WHAT IT IS AND WHAT YOU CAN DO ABOUT IT
URO-GYNECOLOGY PATIIENT IINFORMATIION SHEET FEMALE URINARY INCONTINENCE: WHAT IT IS AND WHAT YOU CAN DO ABOUT IT What is Urinary Incontinence? Stress Incontinence is a leakage of urine that occurs, for
More informationUrinary Incontinence. Lora Keeling and Byron Neale
Urinary Incontinence Lora Keeling and Byron Neale Not life threatening. Introduction But can have a huge impact on quality of life. Two main types of urinary incontinence (UI). Stress UI leakage on effort,
More informationDiagnosis and Treatment of Urinary Incontinence. Urinary Incontinence
Diagnosis and Treatment of Urinary Incontinence Leslee L. Subak, MD Professor Obstetrics, Gynecology & RS Epidemiology, Urology University of California, San Francisco Urinary Incontinence Common - 25%
More informationIncontinence; Lets talk about it. Karanvir Virk M.D. Minimally Invasive and Pelvic Reconstructive Surgery
Incontinence; Lets talk about it Karanvir Virk M.D. Minimally Invasive and Pelvic Reconstructive Surgery Select the most appropriate subtitle for this talk A: Bladders gone wild! B: There s no such thing
More informationPamelor (nortriptyline)
Generic name: Nortriptyline Available strengths: 10 mg, 25 mg, 50 mg, 75 mg capsules; 10 mg/5 ml oral solution Available in generic: Yes Drug class: Tricyclic antidepressant General Information Pamelor
More informationCDEC FINAL RECOMMENDATION
CDEC FINAL RECOMMENDATION MIRABEGRON (Myrbetriq Astellas Pharma Canada Inc.) Indication: Overactive Bladder Recommendation: The Canadian Drug Expert Committee (CDEC) recommends that mirabegron be listed
More informationLatest Press Release. sbn network jimmy swaggart comcast
corp@stantec.com Latest Press Release sbn network jimmy swaggart comcast S i have only been taking optiprostate xts for 8 days and i also take tamsulosin with it. i was taking myrbetriq but it is not all
More informationPRODUCT INFORMATION. Ammonium chloride is an expectorant that has an irritant effect on mucous membranes.
PRODUCT INFORMATION BENADRYL Original Oral Liquid (New Formula) Name of the Medicine Diphenhydramine hydrochloride Ammonium chloride The chemical name for diphenhydramine hydrochloride is 2-(diphenylmethoxy)-N,Ndimethylethanamine
More informationPACKAGE LEAFLET: INFORMATION FOR THE USER Oxybutynin Hydrochloride 3mg Tablets
PACKAGE LEAFLET: INFORMATION FOR THE USER Oxybutynin Hydrochloride 3mg Tablets Read all of this leaflet carefully before you start taking this medicine Keep this leaflet. You may need to read it again.
More informationAREAS OF RESPONSIBILITY FOR THE SHARING OF CARE
Effective Shared Care Agreement (ESCA) Midodrine ESCA: For the treatment of severe orthostatic hypotension due to autonomic dysfunction when corrective factors have been ruled out and other forms of treatment
More informationURODYNAMICS. Your urodynamic study is scheduled at the Ambulatory Procedure Center. This is located at 4-South waiting room at the Altru Main Clinic.
Altru HEALTH SYSTEM URODYNAMICS Your urodynamic study is scheduled at the Ambulatory Procedure Center. This is located at 4-South waiting room at the Altru Main Clinic. Arrival Time: Appointment Date:
More informationKEY MESSAGES. It is often under-recognised and 30-50% of MDD cases in primary care and medical settings are not detected.
KEY MESSAGES Major depressive disorder (MDD) is a significant mental health problem that disrupts a person s mood and affects his psychosocial and occupational functioning. It is often under-recognised
More informationPharmacologic Treatment of Parkinson s Disease. Nicholas J. Silvestri, M.D. Assistant Professor of Neurology
+ Pharmacologic Treatment of Parkinson s Disease Nicholas J. Silvestri, M.D. Assistant Professor of Neurology + Overview n Brief review of Parkinson s disease (PD) n Clinical manifestations n Pathophysiology
More information5 Conservative Treatment for. Pelvic Floor Disorders
5 Conservative Treatment for Pelvic Floor Disorders 23 Pharmacologic Approach to Urinary Incontinence and Voiding Disorders K.-E. Andersson Introduction The main components of the lower urinary tract,
More informationNorpramin (desipramine)
Generic name: Desipramine Available strengths: 10 mg, 25 mg, 50 mg, 75 mg, 100 mg, 150 mg tablets Available in generic: Yes Drug class: Tricyclic antidepressant General Information Norpramin (desipramine)
More information